The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of Clonogenic Common Lymphoid Progenitors in Mouse Bone Marrow
Kondo, M., Weissman, I. L., & Akashi, K. (1997) · Cell · doi:10.1016/s0092-8674(00)80453-5 · Cited by 2,253
Cited by
Natural killer cells and other innate lymphoid cells in cancer
Chiossone, L., Dumas, P.-Y., Vienne, M., & Vivier, E. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0061-z · Cited by 1,007
Self-citationAntitumour actions of interferons: implications for cancer therapy
Parker, B. S., Rautela, J., & Hertzog, P. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.14 · Cited by 907
Natural killer cells in cancer biology and therapy
Wu, S.-Y., Fu, T., Jiang, Y.-Z., & Shao, Z.-M. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01238-x · Cited by 863
Control of Metastasis by NK Cells
López-Soto, A., Gonzalez, S., Smyth, M. J., & Galluzzi, L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.009 · Cited by 736
Self-citationTumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
Gao, Y., Souza-Fonseca-Guimaraes, F., Bald, T., Ng, S. S., Young, A., Ngiow, S. F., Rautela, J., Straube, J., Waddell, N., Blake, S. J., et al. (2017) · Nature Immunology · doi:10.1038/ni.3800 · Cited by 654
Self-citationThe cancer–natural killer cell immunity cycle
Huntington, N. D., Cursons, J., & Rautela, J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0272-z · Cited by 566
Self-citationBCL-2 protein family: attractive targets for cancer therapy
Kaloni, D., Diepstraten, S. T., Strasser, A., & Kelly, G. L. (2023) · Apoptosis · doi:10.1007/s10495-022-01780-7 · Cited by 500
Self-citationThe BCL2 family: from apoptosis mechanisms to new advances in targeted therapy
Vogler, M., Braun, Y., Smith, V. M., Westhoff, M.-A., Pereira, R. S., Pieper, N. M., Anders, M., Callens, M., Vervliet, T., Abbas, M., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02176-0 · Cited by 462
Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors
Melaiu, O., Lucarini, V., Cifaldi, L., & Fruci, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03038 · Cited by 419
A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment
Young, A., Ngiow, S. F., Gao, Y., Patch, A.-M., Barkauskas, D. S., Messaoudene, M., Lin, G., Coudert, J. D., Stannard, K. A., Zitvogel, L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2826 · Cited by 391
Self-citationCIS is a potent checkpoint in NK cell–mediated tumor immunity
Delconte, R. B., Kolesnik, T. B., Dagley, L. F., Rautela, J., Shi, W., Putz, E. M., Stannard, K., Zhang, J.-G., Teh, C., Firth, M., et al. (2016) · Nature Immunology · doi:10.1038/ni.3470 · Cited by 384
Self-citationApoptotic cell death in disease—Current understanding of the NCCD 2023
Vitale, I., Pietrocola, F., Guilbaud, E., Aaronson, S. A., Abrams, J. M., Adam, D., Agostini, M., Agostinis, P., Alnemri, E. S., Altucci, L., et al. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01153-w · Cited by 361
Self-citationAnti-apoptotic BCL-2 family members in development
Opferman, J. T., & Kothari, A. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.170 · Cited by 347
Cursons, J., Souza-Fonseca-Guimaraes, F., Foroutan, M., Anderson, A., Hollande, F., Hediyeh-Zadeh, S., Behren, A., Huntington, N. D., & Davis, M. J. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0500 · Cited by 296
Self-citationBH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
Merino, D., Kelly, G. L., Lessene, G., Wei, A. H., Roberts, A. W., & Strasser, A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.004 · Cited by 287
Self-citationThe Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy
Souza-Fonseca-Guimaraes, F., Cursons, J., & Huntington, N. D. (2019) · Trends in Immunology · doi:10.1016/j.it.2018.12.003 · Cited by 279
Self-citationComplementarity and redundancy of IL-22-producing innate lymphoid cells
Rankin, L. C., Girard-Madoux, M. J. H., Seillet, C., Mielke, L. A., Kerdiles, Y., Fenis, A., Wieduwild, E., Putoczki, T., Mondot, S., Lantz, O., et al. (2016) · Nature Immunology · doi:10.1038/ni.3332 · Cited by 249
“Mcl-1 is an anti-apoptotic protein induced by common γ chain ( γ c) receptor signaling and required for the maintenance of NK cells in vivo 23 .”
Self-citationIL-15 signaling in NK cell cancer immunotherapy
Rautela, J., & Huntington, N. D. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.10.004 · Cited by 125
Self-citationNK cell development requires Tsc1-dependent negative regulation of IL-15-triggered mTORC1 activation
Yang, M., Chen, S., Du, J., He, J., Wang, Y., Li, Z., Liu, G., Peng, W., Zeng, X., Li, D., et al. (2016) · Nature Communications · doi:10.1038/ncomms12730 · Cited by 73
Interferons: role in cancer therapy
Abdolvahab, M. H., Darvishi, B., Zarei, M., Majidzadeh-A, K., & Farahmand, L. (2020) · Immunotherapy · doi:10.2217/imt-2019-0217 · Cited by 50
Metadata
- Authors
- Sathe, P., Delconte, R. B., Souza-Fonseca-Guimaraes, F., Seillet, C., Chopin, M., Vandenberg, C. J., Rankin, L. C., Mielke, L. A., Vikstrom, I., Kolesnik, T. B., Nicholson, S. E., Vivier, E., Smyth, M. J., Nutt, S. L., Glaser, S. P., Strasser, A., Belz, G. T., Carotta, S., & Huntington, N. D.
- Venue
- Nature Communications
- Published
- 2014-08-14
- Volume
- 5
- Issue
- 1
- Pages
- 4539-4539
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2093020827
- Cited by
- 187
- References
- 1
- FWCI
- 6.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.